Argus Research Maintains Buy on Cardinal Health, Raises Price Target to $125
Portfolio Pulse from Benzinga Newsdesk
Argus Research analyst David Toung maintains a Buy rating on Cardinal Health and raises the price target from $115 to $125.
September 11, 2024 | 4:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Argus Research has reaffirmed its Buy rating on Cardinal Health and increased the price target from $115 to $125, indicating confidence in the company's future performance.
The increase in price target from $115 to $125 by Argus Research suggests a positive outlook for Cardinal Health, likely leading to a short-term increase in stock price as investors react to the analyst's confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100